TLX NASDAQ
Telix Pharmaceuticals Limited
1W: -7.9%
1M: -7.9%
3M: -13.2%
YTD: +38.5%
1Y: +3.7%
$10.55
-0.17 (-1.59%)
Weekly Expected Move ±10.7%
$8
$9
$11
$12
$13
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$1.8B
+16.8% ▲
5Y CAGR: +62.2%
Total Liabilities
$1.1B
+21.1% ▲
5Y CAGR: +70.9%
Shareholders Equity
$622M
+9.5% ▲
5Y CAGR: +51.1%
Cash & Investments
$213M
-70.1% ▼
5Y CAGR: +22.2%
Total Debt
$784M
+34.9% ▲
5Y CAGR: +223.7%
Net Debt
$572M
+543.7% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $22M | $116M | $123M | $710M | $213M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $22M | $79M | $123M | $710M | $213M |
| Net Receivables | $21M | $31M | $80M | $159M | $207M |
| Inventory | $3M | $6M | $17M | $38M | $56M |
| Other Current Assets | $0 | $55M | -$8M | $0 | $0 |
| Total Current Assets | $48M | $173M | $225M | $919M | $495M |
| Property, Plant & Equip. | $6M | $19M | $30M | $54M | $173M |
| Goodwill & Intangibles | $60M | $65M | $110M | $416M | $888M |
| Long-Term Investments | $0 | -$6M | $12M | $6M | $56M |
| Other Non-Current Assets | -$4M | $327K | $586K | $75M | $43M |
| Total Non-Current Assets | $62M | $87M | $173M | $598M | $1.3B |
| Total Assets | $110M | $261M | $398M | $1.5B | $1.8B |
| — Liabilities — | |||||
| Accounts Payable | $12M | $17M | $33M | $69M | $107M |
| Short-Term Debt | $19K | $0 | $964K | $19M | $28M |
| Deferred Revenue | $6M | $5M | $11M | $11M | $17M |
| Other Current Liabilities | $14M | $47M | $86M | $110M | $112M |
| Total Current Liabilities | $38M | $86M | $157M | $331M | $347M |
| Long-Term Debt | $0 | $3M | $8M | $552M | $672M |
| Other Non-Current Liab. | $43M | $55M | $60M | $45M | -$49M |
| Total Non-Current Liabilities | $68M | $93M | $92M | $617M | $802M |
| Total Liabilities | $106M | $175M | $249M | $948M | $1.1B |
| — Equity — | |||||
| Common Stock | $171M | $371M | $446M | $597M | $719M |
| Retained Earnings | -$173M | -$273M | -$264M | -$213M | -$232M |
| Accumulated OCI | $5M | -$18M | -$34M | $184M | $135M |
| Total Stockholders Equity | $2M | $80M | $149M | $568M | $622M |
| Total Liabilities & Equity | $110M | $255M | $398M | $1.5B | $1.8B |
| — Key Metrics — | |||||
| Total Debt | $3M | $10M | $17M | $581M | $784M |
| Net Debt | -$19M | -$106M | -$106M | -$129M | $572M |
| Total Investments | $0 | -$6M | $12M | $6M | $56M |